Out of 13 analysts covering Hikma Pharmaceuticals PLC (LON:HIK), 11 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 85% are positive. Hikma Pharmaceuticals PLC has been the topic of 66 analyst reports since September 15, 2015 according to StockzIntelligence Inc. Below is a list of Hikma Pharmaceuticals Plc (LON:HIK) latest ratings and price target changes.
12/09/2016 Broker: Jefferies Rating: Buy Old Target: GBX 2990.00 New Target: GBX 2500.00 Maintain
09/09/2016 Broker: Barclays Capital Rating: Overweight Old Target: GBX 2900.00 New Target: GBX 2900.00 Maintain
25/08/2016 Broker: JP Morgan Rating: Overweight Maintain
24/08/2016 Broker: Numis Securities Rating: Hold Old Target: GBX 2660.00 New Target: GBX 2660.00 Maintain
24/08/2016 Broker: Cantor Fitzgerald Rating: Buy Old Target: GBX 2500.00 New Target: GBX 2500.00 Maintain
23/08/2016 Broker: JP Morgan Rating: Overweight Old Target: GBX 2550.00 New Target: GBX 2550.00 Maintain
16/08/2016 Broker: JP Morgan Rating: Overweight Old Target: GBX 2550.00 New Target: GBX 2550.00 Maintain
12/08/2016 Broker: Morgan Stanley Rating: Equal Weight Old Target: GBX 2700.00 New Target: GBX 2500.00 Maintain
08/08/2016 Broker: Barclays Capital Rating: Overweight New Target: GBX 2900.00 Maintain
04/08/2016 Broker: Numis Securities Rating: Hold New Target: GBX 2660.00 Downgrade
The stock decreased 0.01% or GBX 0.11 on September 13, hitting GBX 2100.89. About 540,424 shares traded hands. Hikma Pharmaceuticals Plc (LON:HIK) has risen 12.05% since February 11, 2016 and is uptrending. It has underperformed by 4.43% the S&P500.
Hikma Pharmaceuticals Plc is a pharmaceutical company. The company has a market cap of 5.01 billion GBP. The Firm develops, makes and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa region and Europe. It has a 33.42 P/E ratio. The Company’s divisions include Branded, Injectables, Generics and Others.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.